| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT07368998 To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With… |
Trial sites expanded: 19 -> 26 locations |
| 2026-06-05 | NCT07287150 A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant… |
Trial sites expanded: 20 -> 32 locations |
| 2026-05-28 | NCT06496568 A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in… |
Primary endpoint(s) modified |
| 2026-05-28 | NCT06496568 A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in… |
Trial arms changed: 3 -> 2 |
| 2026-05-28 | NCT06496568 A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in… |
date change Primary completion moved earlier: 2028-09-28 -> 2027-07-21 |
| 2026-05-28 | NCT06496568 A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in… |
date change Completion moved earlier: 2028-09-28 -> 2027-07-21 |
| 2026-05-27 | NCT04929223 A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of… |
Trial sites expanded: 76 -> 82 locations |
| 2026-05-19 | NCT07347600 A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With… |
Trial sites expanded: 17 -> 22 locations |
| 2026-05-19 | NCT07405801 A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus… |
Trial sites expanded: 19 -> 36 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05862285 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La… | Cancer | Recruiting |
| NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo… | Metastatic Breast Cancer | Recruiting |
| NCT06790693 | A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and… | Breast Cancer | Recruiting |
| NCT05646862 | A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With… | Breast Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT04191499 | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs… | Breast Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05708235 | A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in… | Breast Cancer | Recruiting |
| NCT07405801 | A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus… | Breast Cancer | Recruiting |
| NCT07054190 | A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated… | Breast Cancer | Recruiting |
| NCT07287150 | A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant… | Metastatic Castration-Resistant Prostate Cancer | Recruiting |
| NCT07368998 | To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With… | Breast Cancer | Recruiting |
| NCT07522697 | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 | Endometrial Cancer | Not Yet Recruiting |
| NCT04589845 | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You… | Solid Tumors | Active, Not Recruiting |
| NCT04931342 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With… | Ovarian Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT03424005 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients… | Metastatic Breast Cancer | Recruiting |
| NCT04486352 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | Endometrial Cancer | Recruiting |
| NCT04802759 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in… | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | Recruiting |
| Phase 1 | |||
| NCT04929223 | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of… | Metastatic Colorectal Cancer | Recruiting |
| NCT07144111 | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the… | Hepatic Impairment | Recruiting |
| NCT06496568 | A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in… | PIK3CA-Mutated Cancers | Active, Not Recruiting |
| NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT03006172 | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in… | Breast Cancer | Active, Not Recruiting |
| Not specified | |||
| NCT07347600 | A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With… | Locally Advanced Breast Cancer | Recruiting |